Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,800 shares, a decline of 84.7% from the October 15th total of 11,800 shares. Based on an average trading volume of 27,600 shares, the days-to-cover ratio is currently 0.1 days.

Scinai Immunotherapeutics Trading Down 2.6 %

Shares of NASDAQ:SCNI traded down $0.08 during trading on Tuesday, reaching $3.03. The company had a trading volume of 7,227 shares, compared to its average volume of 312,828. Scinai Immunotherapeutics has a 12 month low of $2.23 and a 12 month high of $8.92. The stock has a market capitalization of $1.76 million, a P/E ratio of -0.01 and a beta of 2.46. The company has a fifty day moving average of $3.60 and a two-hundred day moving average of $3.80.

Scinai Immunotherapeutics (NASDAQ:SCNI) last released its quarterly earnings data on Thursday, August 15th. The company reported ($3.57) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.